Navigation Links
BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
Date:5/23/2013

BOTHELL, Wash., May 23, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the Terrapinn World Stem Cells & Regenerative Medicine Congress 2013 this week in London.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Dr. Aby J. Mathew, BioLife's Senior Vice President and Chief Technology Officer, will make a presentation titled "Critical Stability and Biopreservation Considerations for Manufacturing, Storage and Clinical Delivery of Cell and Tissue Products," to the audience of executives and product development managers of commercial regenerative medicine companies. The presentation outlines the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol® storage and shipping media, and CryoStor® cryopreservation freeze media will be presented on relevant cell and tissue types.

Mike Rice , Chief Executive Officer, commented, "We continue to build traction in the high growth regenerative medicine market, and estimate that more than 65 percent of the presenting companies at this conference have adopted our best in class, clinical grade biopreservation media products.  A key value-added service we provide, which directly translates into expanded product adoption, is the high quality consulting our team offers to prospective and current customers.  Biopreservation outcomes such as cell and tissue shelf life, viability and recovery can greatly impact commercial potential.  The combination of the efficacy and quality of our proprietary platform technology, along with our expert technical consulting services, is now recognized and highly valued in the development and commercialization of regenerative medicine products and therapies."

The regenerative medicine market is expected to grow to more than $35 billion by 2019, according to TriMark Publications' recently published "Regenerative Medicine Markets" report.  BioLife's addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.

For a list of upcoming events, please visit http://biolifesolutions.com/cell-therapy/category/events/.

About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers, and commercial companies significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:

Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300

(949) 474-4300len@allencaron.com

matt@allencaron.com
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Completes First $1 Million Revenue Quarter
2. BioLife Solutions Appoints Rick Stewart To Board of Directors
3. BioLife Solutions Announces 2012 Full Year Results; 10th Consecutive Quarter of Record Revenue
4. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
5. Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions
6. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
7. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
8. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
9. Ablative Solutions Completes $5.3M Series A Financing
10. DATATRAK Expands CDISC Registered Solutions Provider Standards
11. MedNet Solutions to Unveil Innovative New iMedNet EDC Features at The 48th DIA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):